A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread
Status:
Completed
Trial end date:
2016-12-12
Target enrollment:
Participant gender:
Summary
The aim of this study is to see if a drug called nilotinib (Tasigna®) is effective in the
treatment of patients with a rare group of acral and mucosal melanomas that have a change
(mutation) in a protein called cKIT. Nilotinib interferes with signalling inside cells with
this mutation and it is believed that this may lead to shrinkage of tumours. Acral melanomas
are found on the palms and soles and mucosal melanomas start inside body cavities rather than
on the skin.